Drugs that contain Sildenafil Citrate
1. Liqrev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337979 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(15 years from now) | |
| US11464778 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(15 years from now) | |
Market Authorisation Date: 28 April, 2023
Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening
Dosage: SUSPENSION;ORAL
More Information on Dosage
LIQREV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic